NASDAQ:FLXN - Flexion Therapeutics Stock Price, Forecast & News

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics Inc (NASDAQ:FLXN) issued its earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.01) by $0.01. The specialty pharmaceutical company earned $21.79 million during the quarter, compared to the consensus estimate of $18.85 million. Flexion Therapeutics had a negative return on equity of 271.22% and a negative net margin of 266.51%. View Flexion Therapeutics' Earnings History.

Flexion Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Flexion Therapeutics.

Flexion Therapeutics updated its fourth quarter 2019 After-Hours earnings guidance on Thursday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $23.7-23.7 million, compared to the consensus revenue estimate of $24.15 million.

9 analysts have issued 12-month price targets for Flexion Therapeutics' shares. Their forecasts range from $18.00 to $36.00. On average, they expect Flexion Therapeutics' share price to reach $25.88 in the next twelve months. This suggests a possible upside of 49.5% from the stock's current price. View Analyst Price Targets for Flexion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Flexion Therapeutics.

News articles about FLXN stock have been trending very positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Flexion Therapeutics earned a news impact score of 3.1 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Flexion Therapeutics.

Some companies that are related to Flexion Therapeutics include ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Principia Biopharma (PRNB), Aurinia Pharmaceuticals (AUPH), Ra Pharmaceuticals (RARX), Synthorx (THOR), Prestige Consumer Healthcare (PBH), Turning Point Therapeutics (TPTX), Forty Seven (FTSV), Xencor (XNCR), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX) and Cambrex (CBM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), Synergy Pharmaceuticals (SGYP), Aduro BioTech (ADRO), Cara Therapeutics (CARA), Verastem (VSTM), TherapeuticsMD (TXMD), AcelRx Pharmaceuticals (ACRX), Omeros (OMER), Gilead Sciences (GILD) and Amicus Therapeutics (FOLD).

Flexion Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (4.36%), Artisan Partners Limited Partnership (2.19%), Gagnon Securities LLC (1.91%), Schroder Investment Management Group (1.60%), Peregrine Capital Management LLC (1.54%) and Geode Capital Management LLC (1.24%). Company insiders that own Flexion Therapeutics stock include C Ann Merrifield, David Arkowitz, Mark S Levine, Michael D Clayman, Neil Bodick and Samuel D Colella. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Peregrine Capital Management LLC, Campbell Capital Management Inc., UBS Group AG, Gagnon Securities LLC, Bank of America Corp DE, Rafferty Asset Management LLC and Renaissance Technologies LLC. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, State Street Corp, Madison Asset Management LLC, Castleark Management LLC, Cubist Systematic Strategies LLC, EAM Global Investors LLC, EAM Investors LLC and Snow Capital Management LP. Company insiders that have bought Flexion Therapeutics stock in the last two years include C Ann Merrifield, David Arkowitz, Michael D Clayman and Samuel D Colella. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $17.31.

Flexion Therapeutics has a market capitalization of $660.72 million and generates $22.52 million in revenue each year. The specialty pharmaceutical company earns $-169,660,000.00 in net income (profit) each year or ($4.49) on an earnings per share basis. Flexion Therapeutics employs 272 workers across the globe.View Additional Information About Flexion Therapeutics.

The official website for Flexion Therapeutics is http://www.flexiontherapeutics.com/.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]